Immunoreactive Trypsinogen in Infants Born to Women with Cystic Fibrosis Taking Elexacaftor–Tezacaftor–Ivacaftor

Most people with cystic fibrosis (CF) are diagnosed following abnormal newborn screening (NBS), which begins with measurement of immunoreactive trypsinogen (IRT) values. A case report found low concentrations of IRT in an infant with CF exposed to the CF transmembrane conductance regulator (CFTR) mo...

Full description

Bibliographic Details
Published in:	International Journal of Neonatal Screening
Main Authors:	Payal Patel, Jana Yeley, Cynthia Brown, Melissa Wesson, Barbara G. Lesko, James E. Slaven, James F. Chmiel, Raksha Jain, Don B. Sanders
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Subjects:	cystic fibrosis newborn screening immunoreactive trypsinogen
Online Access:	https://www.mdpi.com/2409-515X/9/1/10

Similar Items

Missed Cystic Fibrosis Newborn Screening Cases due to Immunoreactive Trypsinogen Levels below Program Cutoffs: A National Survey of Risk Factors
by: Martin Kharrazi, et al.
Published: (2022-10-01)

Biological Reference Intervals for 17α-Hydroxyprogesterone Immunoreactive Trypsinogen, and Biotinidase in Indian Newborns
by: E. Maruthi Prasad, et al.
Published: (2024-08-01)

Pancreatitis-Associated Protein in Neonatal Screening for Cystic Fibrosis: Strengths and Weaknesses
by: Olaf Sommerburg, et al.
Published: (2020-03-01)

Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation
by: Steven J Edwards, et al.
Published: (2025-05-01)

Impact of elexacaftor/tezacaftor/ivacaftor on the small airways in cystic fibrosis
by: Sofia Campos Silva, et al.
Published: (2025-06-01)

Performance of a Three-Tier (IRT-DNA-IRT) Cystic Fibrosis Screening Algorithm in British Columbia
by: Graham Sinclair, et al.
Published: (2020-06-01)

Investigating CFTR gene variations in patient groups with positive newborn screening test results and preliminary clinical diagnosis of cystic fibrosis in the eastern anatolia region of Turkey
by: Ayberk Turkyilmaz, et al.
Published: (2021-06-01)

Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor
by: L. Gómez-Ganda, et al.
Published: (2024-06-01)

Communication of carrier status information following universal newborn screening for sickle cell disorders and cystic fibrosis: qualitative study of experience and practice
by: J Kai, et al.
Published: (2009-11-01)

Neonatal Screening for Cystic Fibrosis in Hungary—First-Year Experiences
by: Andrea Xue, et al.
Published: (2023-08-01)

Proteomics profiling of inflammatory responses to elexacaftor/tezacaftor/ivacaftor in cystic fibrosis
by: Hazel Ozuna, et al.
Published: (2025-01-01)

Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic Fibrosis
by: Ngoc Hoa Truong, et al.
Published: (2025-05-01)

Impact of elexacaftor-tezacaftor-ivacaftor in lung transplantation for cystic fibrosis in the United States
by: Tahuanty A. Pena, MD, MS, et al.
Published: (2025-02-01)

Cystic fibrosis liver disease progression in the era of elexacaftor–tezacaftor–ivacaftor
by: Charlotte Mouliade, et al.
Published: (2025-10-01)

Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review
by: Nikoletta Kapouni, et al.
Published: (2023-03-01)

Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
by: Linus Piehler, et al.
Published: (2023-04-01)

Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor
by: Seth A. Reasoner, et al.
Published: (2024-02-01)

Unveiling the psychosocial impact of Elexacaftor/Tezacaftor/Ivacaftor therapy in Cystic Fibrosis patients
by: Marta Solís García, et al.
Published: (2025-02-01)

Analysis of Depression and Anxiety Scores Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Adults With Cystic Fibrosis
by: Harish Pudukodu, et al.
Published: (2024-09-01)

Trypsin and Trypsinogen Activation Peptide in the Prediction of Severity of Acute Pancreatitis
by: Andreas Allemann, et al.
Published: (2024-08-01)

Engineering mouse chymotrypsin B1 for improved trypsinogen degradation
by: Nataly C. Morales Granda, et al.
Published: (2025-03-01)

Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy
by: Dirk Westhölter, et al.
Published: (2023-02-01)

Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis
by: Thomas Keens, et al.
Published: (2024-04-01)

Cystic Fibrosis Newborn Screening: A Systematic Review-Driven Consensus Guideline from the United States Cystic Fibrosis Foundation
by: Meghan E. McGarry, et al.
Published: (2025-04-01)

Evolution of Lung Disease Studied by Computed Tomography in Adults with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor
by: Susana Hernández-Muñiz, et al.
Published: (2025-04-01)

Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
by: Marika Comegna, et al.
Published: (2021-07-01)

Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor–Tezacaftor–Ivacaftor therapy
by: Christian Martin, et al.
Published: (2023-12-01)

Efficacy and safety of using Elexacaftor/Tezacaftor/Ivacaftor in the treatment of children with cystic fibrosis: real-world evidence from Brazil
by: Guilherme da Silva Martins, et al.
Published: (2025-09-01)

Multimodal analysis of granulocytes, monocytes, and platelets in patients with cystic fibrosis before and after Elexacaftor–Tezacaftor–Ivacaftor treatment
by: Hanna Schmidt, et al.
Published: (2023-06-01)

Elexacaftor-Tezacaftor-Ivacaftor in 2 cystic fibrosis adults homozygous for M1101K with end-stage lung disease
by: Winnie M. Leung, et al.
Published: (2023-01-01)

Cystic fibrosis pathogens persist in the upper respiratory tract following initiation of elexacaftor/tezacaftor/ivacaftor therapy
by: Yasmin Hilliam, et al.
Published: (2024-08-01)

Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
by: Eva Choong, et al.
Published: (2022-08-01)

CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy
by: Hanna Crow, et al.
Published: (2022-12-01)

Response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis with the N1303K mutation: Case report and review of the literature
by: Maria G. Tupayachi Ortiz, et al.
Published: (2024-03-01)

Longitudinal improvements in clinical and functional outcomes following initiation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis
by: Kadambari Vijaykumar, et al.
Published: (2024-04-01)

Value of Urinary Trypsinogen-2 Test in Early Diagnosis of Pancreatitis after Endoscopic Retrograde Cholangiopancreatography (ERCP)
by: Ahlam Mohammed Sabra, et al.
Published: (2025-07-01)

Increased fat mass and obesity risk after elexacaftor–tezacaftor–ivacaftor therapy in young adults with cystic fibrosis
by: Ana Merino Sánchez-Cañete, et al.
Published: (2024-11-01)

Resolution of long standing hypergammaglobulinemic purpura of Waldenström after initiating treatment for cystic fibrosis with Elexacaftor–Tezacaftor–Ivacaftor
by: Kimberly Tantuco, MD, et al.
Published: (2024-02-01)

Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on Aspergillus fumigatus growth
by: Elise Biquand, et al.
Published: (2025-09-01)

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
by: Lijia Zhang, et al.
Published: (2022-12-01)